Dipna Pharmachem Ltd

Dematerialisation status

• No dematerialisation/rematerialisation requests were received during the period.
• No certificates were mutilated or cancelled, and no depository name substitution occurred.

Key financial and governance updates

• Standalone audited results for Q4 and year ended 31 March 2026.
• Audit Committee reviewed and Board approved results on 2 July 2026.
• First-time IND AS adoption during the period.
• Full-year revenue from operations: 12,908.33 Lakh; total income: 12,910.87 Lakh.
• Net profit: 263.19 Lakh; basic/diluted EPS: 1.00.
• Chemicals segment loss 512.35 Lakh; Steel segment profit 866.83 Lakh; total 354.48 Lakh.
• Convertible warrants raised: 22.44 lakh shares; 75% received; funds allocated to working capital and corporate purposes; no deviation.
• Related party transactions include loans and commissions with director-related entities; no defaults reported.
• Independent Auditor's Report issued unmodified opinion.
• Company has no subsidiary.

Deviation in fund utilisation

• Mode of fund raising: Preferential issue with convertible warrants.
• Date of fund raising: disclosed in filing (no specific date listed here).
• Proceeds raised: described as receipts under warrants; total amount disclosed in filing.
• Deviation/variation: none.
• Shareholder approval: not applicable.
• Audit Committee comments: none.
• Auditors' comments: none.
• Monitoring agency: not applicable.
• Objects: original vs modified table present; no deviation.
• Utilisation status: no deviation; utilisation details not provided.

Resigning director details

• Nandish Shaileshbhai Jani, Non-Executive and Independent Director, resigns effective 10 June 2026.
• Reason: personal reasons.
• There are no other material reasons beyond those in the resignation letter.
• Directorships held: Magenta Lifecare Limited (Independent Director); AKI India Limited (Independent Director).
• Magenta Lifecare roles: Audit Committee Chair; Stakeholders' Relationship Committee Chair; Nomination and Remuneration Committee Member.
• AKI India Limited roles: Audit Committee Member; Nomination and Remuneration Committee Member; Stakeholders' Relationship Committee Member.
• Regulatory/ shareholder approvals: Not mentioned in the filing.
• No immediate changes to board/committee composition disclosed.

Director resignation details

• Parin Bhavsar resigns as Non-Executive and Independent Director of Dipna Pharmachem Limited.
• Resignation effective date: 12 May 2026.
• Reason: due to pre-occupancy.
• Confirmed there are no other material reasons beyond the resignation letter.
• Listed entity: Chandrima Mercantiles Limited — Independent Director.
• Chandrima Mercantiles Limited: Audit Committee — Member.
• Chandrima Mercantiles Limited: Nomination and Remuneration Committee — Member.
• Chandrima Mercantiles Limited: Stakeholders' Relationship Committee — Member.
• No regulatory or shareholder approval indicated as required for resignation.
• No immediate board or committee changes disclosed.

Appointments

• Appointed Mr. J. P. Parmar (DIN 09699769) as Additional Non-Executive Independent Director, 11 May 2026.
• Appointed Mr. Manish Shrichand Bachani (DIN 08013906) as Additional Non-Executive Independent Director, 11 May 2026.

Committee Reconstitutions

• Reconstituted Audit Committee; Parmar as Chairperson, Bachani and Dipna Keyur Shah as Members, effective 11 May 2026.
• Reconstituted Nomination & Remuneration Committee; Parmar as Chairperson, Bachani and Dipna Keyur Shah as Members.
• Reconstituted Stakeholders Relationship Committee; Parmar as Chairperson, Bachani and Dipna Keyur Shah as Members.

Rescheduled meeting

• Board meeting rescheduled from 1 July 2026 to 2 July 2026 at 04:00 PM.
• Original date: 1 July 2026; new date: 2 July 2026.
• Agenda includes Audited Financial Results and Auditor’s Report for HY and FY ended 31 March 2026.
• Other matters to be discussed with permission of Chairperson.

Dipna Pharmachem Ltd — Trading Window closed from Wednesday, 1st July, 2026 till 48 hours after the declaration and publication of Unaudited Financial Results for the Quarter ended 30th June, 2026